Advertisement

Drug Discovery at the Enzyme Level

  • Ray W. Fuller
  • Larry R. Steranka

Abstract

This chapter deals with enzymes as targets of drug action. The focus is on inhibition of enzyme activity by drugs, although other actions of drugs on enzymes are possible, such as activation or allosteric modification of enzyme function. This chapter will not deal with enzymes themselves as drugs, e. g., L-asparaginase in the treatment of acute lymphocytic leukemia, papain used for proteolysis in wound debridement, and urokinase used in thrombolytic therapy. Metabolism of drugs by enzymes and inhibition or induction of drug-metabolizing enzymes are other drug-enzyme interactions that can be important considerations in drug development, but our focus will be entirely on drug inhibition of enzymes as a primary mechanism to which drugs owe their efficacy. We will consider how enzyme activity is assayed, how inhibitors are found (or made) and characterized, how enzyme inhibition is demonstrated in vivo, and some specific examples of enzyme inhibitors that are used as drugs.

Keywords

Enzyme Inhibitor Drug Discovery Xanthine Oxidase Monoamine Oxidase Competitive Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ackermann, W. W. and Potter, V. R. (1949) Enzyme inhibition in relation to chemotherapy. Proc. Soc. Exp. Biol. Med. 72, 1–9.PubMedGoogle Scholar
  2. Antonaccio, M.J. (1982) Angiotensin converting enzyme (ACE) inhibitors. Ann. Rev. Pharmacol. Toxicol. 22, 57–87.CrossRefGoogle Scholar
  3. Ask, A.-L., Fagervall, I., and Ross, S. B. (1983) Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain. Naunyn-Schmiedeberg’s Arch. Pharmacol. 324, 79–87.CrossRefGoogle Scholar
  4. Baldessarini, R. J. and Greiner, E. (1973) Inhibition of catechol-O-methyl transferase by catechols and polyphenols. Biochem. Pharmacol. 22, 247–256.PubMedCrossRefGoogle Scholar
  5. Barrett, A. J. (1980) Proteinase Inhibitors: Potential Drugs?, in Enzyme Inhibitors as Drugs ( Sandler, M., ed.) University Park Press, Baltimore, Maryland.Google Scholar
  6. Bartholini, G. and Pletscher, A. (1969) Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine. J. Pharm. Pharmacol. 21, 323–324.PubMedCrossRefGoogle Scholar
  7. Bondinell, W. E., Chapin, F. W., Frazee, J. S., Girard, G. R., Holden, K. G., Kaiser, C., Maryanoff, C., and Perchonock, C. D. (1983) Inhibitors of phenylethanolamine N-methyltransferase and epinephrine biosynthesis: A potential source of new drugs. Drug Metab. Rev. 14, 709–721.PubMedCrossRefGoogle Scholar
  8. Borchardt, R. T. (1977) Synthesis and Biological Activity of Analogues of Adenosylhomocysteine as Inhibitors of Methyltransferases, in The Biochemistry of S-Adenosylmethionine ( Salvatore, F., Borek, E., Zappia, V., Williams-Ashman, H. G., and Schlenk, F., eds.) Columbia University Press, New York.Google Scholar
  9. Brannon, D. R. and Fuller, R. W. (1974) Microbial production of pharmacologically active compounds other than antibiotics. Lloydia 37, 134–146.PubMedGoogle Scholar
  10. Cheng, Y.-C. and Prusoff, W. H. (1973) Relationship between the inhibition constant (K,) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108.PubMedCrossRefGoogle Scholar
  11. Cleland, W. W. (1967) The statistical analysis of enzyme kinetic data. Adv. Enzymol. 29, 1–32.PubMedGoogle Scholar
  12. Davidson, J., Zung,W. W. K., and Walker, J. I. (1984) Practical aspects of MAO inhibitor therapy. J. Clin. Psychiatr. 45, 81–84.Google Scholar
  13. Duch, D. S., Bowers, S., Edelstein, M., and Nichol, C. A. (1979) Histamine: Elevation of Brain Levels by Inhibition of Histamine N-methyl Transferase, in Transmethylation ( Usdin, E., Borchardt, R. T., and Creveling, C. R., eds.) Elsevier/North-Holland, New York, Amsterdam, London.Google Scholar
  14. Elion, G. B. (1978) Allopurinol and Other Inhibitors of Urate Synthesis, in Handbook of Experimental Pharmacology vol. 51 Uric Acid ( Kelley, W. N. and Weiner, I. M., eds.) Springer-Verlag, Berlin.Google Scholar
  15. Fahn, S., Comi, R., Snider, S. R., and Prasad, A. L. N. (1979) Effect of a catechol-O-methyl transferase inhibitor, U-0521, with levodopa administration. Biochem. Pharmacol. 28, 1221–1225.PubMedCrossRefGoogle Scholar
  16. Frere, J. M., Duez, C., Dusart, J., Coyette, J., Leyh-Bouille, M., Ghuysen, J. M., Dideberg, O., and Knox, J. (1980) Mode of Action of β-Lactam Antibiotics at the Molecular Level, in Enzyme Inhibitors as Drugs ( Sandler, M., ed.) University Park Press, Baltimore, Maryland.Google Scholar
  17. Fritz, H. and Wunderer, G. (1983) Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittel-Forsch. 33 (1), 479–494.Google Scholar
  18. Fuller, R. W. (1972) Selective inhibition of monoamine oxidase. Adv. Biochem. psychopharmacol. 5, 339–354.PubMedGoogle Scholar
  19. Fuller, R. W. (1978) Selectivity among monoamine oxidase inhibitors and its possible importance for development of antidepressant drugs. Progr. Neuro-Psychopharmacol. 2, 303–311.CrossRefGoogle Scholar
  20. Fuller, R. W. and Hemrick-Luecke, S. K. (1985) Inhibition of types A and B monoamine oxidase by l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. J. Pharmacol. Exp. Ther. 232, 696–701.PubMedGoogle Scholar
  21. Fuller, R. W. and Nagarajan, R. (1978) Inhibition of methyltransferases by some new analogs of S–adenosvlhomocysteine. Biochem. Pharmacol. 27, 1981–1983.PubMedCrossRefGoogle Scholar
  22. Fuller, R. W., Ho, P. P. K., Matsumoto, C., and Clemens, J. A. (1977) New inhibitors of dopamine β-hydroxylase. Adv. Em. Regul. 15, 267–281.CrossRefGoogle Scholar
  23. Fuller, R. W., Snoddy, H. D., and Perry, K. W. (1982) Dopamine accumulation after dopamine β-hydroxylase inhibition in rat heart as an index of norepinephrine turnover. Life Sci. 31, 563–570.PubMedCrossRefGoogle Scholar
  24. Green, A. L. and El Hait, M. A. S. (1980) A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors invivo), and its application to (+)-amphetamine, p-methoxyamphetamine and harmaline. Biochem. Pharmacol. 29, 2781–2789.PubMedCrossRefGoogle Scholar
  25. Horita, A. and McGrath, W. R. (1960) The interaction between reversible and irreversible monoamine oxidase inhibitors. Biochem. Pharmacol. 3, 206–211.PubMedCrossRefGoogle Scholar
  26. Kalman, T. I. (1979) Drug Action and Design: Mechanism-Based Enzyme Inhibitors. Elsevier/North-Holland, New York, Amsterdam, Oxford.Google Scholar
  27. Lienhard, G. E. (1980) Transition-State Analogues, in Enzyme Inhibitors as Drugs ( Sandler, M., ed.) University Park Press, Baltimore, Maryland.Google Scholar
  28. Lipinski, C. A. and Hutson, N. J. (1984) Aldose reductase inhibitors as a new approach to the treatment of diabetic complications. Ann. Repts. Med. Chem. 19, 169–177.CrossRefGoogle Scholar
  29. Moncada, S. and Vane, J. R. (1980) Inhibitors of Arachidonic Acid Metabolism, in Enzyme Inhibitors as Drugs ( Sandler, M., ed.) University Park Press, Baltimore, Maryland.Google Scholar
  30. Ortmann, R., Schaub, M., Felner, A., Lauber, J., Christen, P., and Waldmeier, P. C. (1984) Phenylethylamine-induced stereotypies in the rat: A behavioral test system for assessment of MAO-B inhibitors. Psychopharmacology 84, 22–27.PubMedCrossRefGoogle Scholar
  31. Penning, T. M. (1983) Design of suicide substrates: An approach to the development of highly selective enzyme inhibitors as drugs. Trends Pharmacol. Sci. 4, 212–217.CrossRefGoogle Scholar
  32. Planz, G., Palm, D., and Quiring, K. (1973) On the evaluation of weak and reversible inhibitors of monoamine oxidase in vivo and in vitro. Arzneimittel-Forsch. 23, 281–285.Google Scholar
  33. Pletscher, A. and Besendorf, H. (1959) Antagonism between harmaline and long-acting monoamine oxidase inhibitors concerning the effect on 5-hydroxytryptamine and norepinephrine metabolism in the brain. Experientia 15, 25–26.PubMedCrossRefGoogle Scholar
  34. Porter, C. C., Watson, L. S., Titus, D. C., Totaro, J. A., and Byer, S. S. (1962) Inhibition of the dopa decarboxylase by the hydrazino analog of α-methyldopa. Biochem. Pharmacol. 11, 1067–1077.PubMedCrossRefGoogle Scholar
  35. Quitkin, F., Rifkin, A., and Klein, D. F. (1979) Monoamine oxidase inhibitors. Arch. Gen. Psychiat. 36, 749–760.PubMedGoogle Scholar
  36. Rajashekhar, B., Fitzpatric, P. F., Colombo, G., and Villafranca, J. J. (1984) Synthesis of several 2 substituted 3-(p-hydroxyphenyl)-1-propenes and their characterization as mechanism based inhibitors of dopamine β-hydroxylase. J. Biol. Chem. 259, 6925–6930.PubMedGoogle Scholar
  37. Rando, R. R. (1974) Chemistry and enzymology of kcat inhibitors. Science 185, 320–324.PubMedCrossRefGoogle Scholar
  38. Silverman, R. B. (1983) Objection to terminology used in special reports. Chem. Eng. News 61 (43), 2.Google Scholar
  39. Sjoerdsma, A. (1981) Suicide enzyme inhibitors as potential drugs. Clin. Pharmacol. Ther. 30, 3–22.PubMedCrossRefGoogle Scholar
  40. Sjoerdsma, A. and von Studnitz, VV. (1963) Dopamine-β-oxidase activity in man, using hydroxyamphetamine as substrate. Br. J. Pharmacol. Chemother. 20, 278–284.PubMedGoogle Scholar
  41. Srere, P. A. (1967) Enzyme concentrations in tissues. Science 158, 936–937.PubMedCrossRefGoogle Scholar
  42. Umezawa, H. (1982) Low-molecular-weight enzyme inhibitors of microbial origin. Ann. Rev. Microbiol. 36, 75–99.CrossRefGoogle Scholar
  43. Waldmeier, P. C. and Baumann. P. A. (1983) Effects of CGP 11305A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 324, 20–26.PubMedCrossRefGoogle Scholar
  44. Webb, J. L. (1963) Enzyme and Metabolic Inhibitors. Academic, New York.Google Scholar
  45. Wilkinson, G. N. (1961) Statistical estimations in enzyme kinetics. Biochem. J. 80, 324–332.PubMedGoogle Scholar
  46. Wolfenden, R. (1976) Transition state analog inhibitors and enzyme catalysis. Ann. Rev. Biophus. Bioeng. 5, 271–306.CrossRefGoogle Scholar

Copyright information

© The Humana Press Inc. 1987

Authors and Affiliations

  • Ray W. Fuller
  • Larry R. Steranka

There are no affiliations available

Personalised recommendations